Brokerages Set Caladrius Biosciences Inc (NASDAQ:CLBS) Price Target at $10.50

Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $10.50.

CLBS has been the topic of several analyst reports. Chardan Capital reiterated a “buy” rating and set a $6.00 target price on shares of Caladrius Biosciences in a report on Friday, May 15th. Brookline Capital Management initiated coverage on Caladrius Biosciences in a report on Monday, May 25th. They set a “buy” rating and a $7.00 target price on the stock. Dawson James downgraded Caladrius Biosciences from a “buy” rating to a “neutral” rating in a report on Monday, May 18th. Zacks Investment Research downgraded Caladrius Biosciences from a “buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.50 target price on shares of Caladrius Biosciences in a report on Friday, May 8th.

An institutional investor recently bought a new position in Caladrius Biosciences stock. Summit Trail Advisors LLC acquired a new position in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) during the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 17,730 shares of the biotechnology company’s stock, valued at approximately $32,000. Summit Trail Advisors LLC owned about 0.14% of Caladrius Biosciences as of its most recent SEC filing. 6.60% of the stock is owned by institutional investors and hedge funds.

Shares of Caladrius Biosciences stock traded down $0.11 during trading hours on Friday, reaching $1.79. The stock had a trading volume of 281,760 shares, compared to its average volume of 226,102. The firm has a 50 day simple moving average of $1.89 and a two-hundred day simple moving average of $2.31. The firm has a market capitalization of $24.40 million, a price-to-earnings ratio of -0.99 and a beta of 1.49. Caladrius Biosciences has a 1 year low of $1.05 and a 1 year high of $3.64.

Caladrius Biosciences (NASDAQ:CLBS) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.09). On average, equities analysts predict that Caladrius Biosciences will post -1.51 earnings per share for the current fiscal year.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Read More: The basics of gap trading strategies

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.